Zyban (bupropion hydrochloride) is a prescription medication specifically developed to support adults in their journey to quit smoking. As a non-nicotine-based therapy, it functions by targeting neurochemical pathways in the brain associated with nicotine addiction and withdrawal. Clinical studies have demonstrated its efficacy in reducing cravings and withdrawal symptoms, helping patients achieve long-term abstinence from tobacco. It is an integral component of a comprehensive smoking cessation program, which may include behavioral support and counseling.

Features

• Active ingredient: Bupropion hydrochloride
• Available in sustained-release (SR) tablet formulation
• Dosage strengths: 150 mg
• Prescription-only medication
• Non-nicotine therapeutic approach
• Manufactured under strict pharmaceutical quality standards

Benefits

• Reduces the intensity of nicotine cravings and withdrawal symptoms
• Helps break the psychological and physical addiction to smoking
• Increases the likelihood of long-term smoking cessation success
• Does not contain nicotine, avoiding replacement dependency
• Can be used as part of a broader cessation strategy
• Supported by extensive clinical research and real-world evidence

Common use

Zyban is indicated as an aid to smoking cessation treatment in adults. It is prescribed for patients motivated to quit smoking who may benefit from pharmacological support to manage withdrawal symptoms and cravings. The medication is typically initiated while the patient is still smoking, with a target quit date set within the first two weeks of treatment. Healthcare providers often recommend combining Zyban with behavioral support or counseling programs for optimal results.

Dosage and direction

The recommended dosage is one 150 mg tablet daily for the first three days, followed by one 150 mg tablet twice daily thereafter. Tablets should be swallowed whole and not crushed, divided, or chewed. Doses should be taken at least 8 hours apart. The treatment duration is typically 7-12 weeks, though some patients may require longer therapy under medical supervision. Treatment should not exceed 150 mg twice daily. Patients should follow their healthcare provider’s specific instructions regarding timing and duration of therapy.

Precautions

Patients should be monitored for neuropsychiatric symptoms including changes in behavior, hostility, agitation, depressed mood, and suicidal thoughts or behavior. Use with caution in patients with a history of seizure disorder or conditions that may lower seizure threshold. Hepatic impairment requires dosage adjustment or avoidance. Renal impairment may affect drug elimination. May cause elevated blood pressure—monitor regularly. Use caution when operating machinery until response to treatment is known. Not recommended during pregnancy unless potential benefit justifies potential risk.

Contraindications

Hypersensitivity to bupropion or any component of the formulation. Current or prior diagnosis of bulimia or anorexia nervosa. Use of monoamine oxidase inhibitors (MAOIs) within 14 days. Patients undergoing abrupt discontinuation of alcohol or sedatives. History of seizure disorder. Patients with known central nervous system tumors. Severe hepatic cirrhosis.

Possible side effects

Common side effects (≥1%) include dry mouth, insomnia, headache, nausea, dizziness, pharyngitis, constipation, anxiety, agitation, and tremor. Less common but serious side effects may include seizures, severe allergic reactions, hypertension, psychiatric symptoms, angle-closure glaucoma, and hepatotoxicity. Patients should report any unusual symptoms to their healthcare provider promptly.

Drug interaction

MAO inhibitors (contraindicated within 14 days of use). Drugs that lower seizure threshold (antidepressants, antipsychotics, systemic corticosteroids). Drugs metabolized by CYP2D6 (dose adjustment may be needed). Levodopa and amantadine (increased risk of adverse effects). Drugs that affect dopamine levels. Alcohol (may increase risk of neuropsychiatric events). Nicotine replacement therapy (may increase hypertension risk).

Missed dose

If a dose is missed, skip the missed dose and take the next dose at the regularly scheduled time. Do not double the dose to make up for a missed dose. Patients should maintain the regular dosing schedule and contact their healthcare provider if multiple doses are missed or if unsure about how to proceed.

Overdose

Overdose may cause seizures, hallucinations, loss of consciousness, sinus tachycardia, and ECG changes. Multiple overdose cases have included fatalities. Management requires immediate medical attention with supportive measures. Airway protection may be necessary. ECG monitoring is essential. There is no specific antidote; treatment should focus on symptom management and seizure control.

Storage

Store at room temperature (20-25°C/68-77°F). Excursions permitted to 15-30°C (59-86°F). Keep in original container, tightly closed. Protect from light and moisture. Keep out of reach of children and pets. Do not use after expiration date. Properly dispose of unused medication according to local regulations.

Disclaimer

This information is for educational purposes only and does not replace professional medical advice. Always consult a qualified healthcare provider for diagnosis and treatment decisions. Individual results may vary. Full prescribing information should be reviewed before initiation of therapy.

Reviews

Clinical trials demonstrate approximately 30-35% continuous abstinence rates at one year compared to 16% with placebo. Real-world evidence supports its effectiveness across diverse patient populations. Patients report reduced craving intensity and improved quit success when used as directed. Healthcare providers note its value in comprehensive cessation programs. Long-term follow-up studies show sustained benefit for many patients.